secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001104659-24-114136
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q3 net loss $31.2M; cash $244.7M, expands CNTY-101 autoimmune trial, 83% ORR in lymphoma
--------------------------------------------------------------------------------

- Net loss $31.2M in Q3 2024; cash $244.7M; expects cash to support operations into H2 2026.
- Expanded CNTY-101 autoimmune trial to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy; basket protocol.
- ELiPSE-1 interim: 83% ORR, 33% CRR at DL3B; no DLTs or high-grade CRS/ICANS; DL4B dosing initiated.
- Strategic pipeline review to conclude Q1 2025; organizational restructuring extended cash runway.
- Appointed Morgan Conn CFO and Chad Cowan CSO; Hy Levitsky transitioned to advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924114136/0001104659-24-114136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465924114136/tm2427432d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-114136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer